英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • American 7s Football League - National 7v7 Tackle Football
    Boca Raton, FL – OCT 21, 2025 – The American 7s Football League (A7FL®) today announced key dates for its 2026 The American 7s Football League (A7FL) has carved out a distinctive niche in professional football with its 7-on-7, no-helmets, no-pads format,
  • CheckMate 7FL Neoadjuvant Immunochemotherapy in ER-Positive . . .
    CheckMate-7FL involved 510 patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer, which accounts for around 70% of cases of the disease Results of the trial were published in Nature Medicine by Sherene Loi, MD, PhD, and colleagues
  • Neoadjuvant nivolumab and chemotherapy in early estrogen . . .
    In the CheckMate 7FL study, we investigated whether the addition of nivolumab to anthracycline and taxane neoadjuvant CT could significantly increase pCR rates in newly diagnosed early-stage,
  • Study of Nivolumab Versus Placebo in Combination With . . .
    Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL)
  • Neoadjuvant Chemotherapy and Immunotherapy for Estrogen . . .
    In summary, results from the CheckMate-7FL, KEYNOTE-756, and immunotherapy arms of I-SPY2 trial raise the possibility that recurrence-free survival could be further improved in selected high-risk ER+ HER2– cancers
  • New treatment boosts cure rate for most common form of breast . . .
    The Phase III CheckMate-7FL trial involved 510 people with the “ER+ HER2-” sub-type which accounts for around 70% of all breast cancers These patients receive chemotherapy to shrink their tumour making it easier to surgically remove
  • Study: Patients With PD-L1-Positive, High-Risk, ER+ HER2 . . .
    The CheckMate 7FL study is a prospective, phase 3, randomized, multicenter, double-blind trial investigating the addition of nivolumab (Opdivo; Bristol Myers Squibb) to neoadjuvant chemotherapy and adjuvant endocrine therapy in patients with high-risk, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative
  • Key Immunotherapy Presentations in Early Breast Cancer from . . .
    Unlike triple negative disease, the relationship of pCR to EFS in the setting of hormone receptor-positive HER2-negative cancer is far less clear, so while the KN-756 and CM-7FL presentations are intriguing, they are not practice-changing
  • Phase III CheckMate 7FL: Biomarker Analysis of Addition of . . .
    CheckMate 7FL: phase III trial comparing addition of nivolumab vs placebo to NACT and then adjuvant ET in patients with high-risk, high-grade ER+ HER2- primary breast cancer1 Trial met primary endpoint, demonstrating that addition of nivolumab to NACT and adjuvant ET significantly improved pCR rate vs placebo (24 5% vs 13 8%, respectively; P
  • LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs . . .
    High-risk, early-stage ER+ HER2− BC treatment includes NACT and adjuvant ET CheckMate 7FL (CM-7FL; NCT04109066) is the first prospective, phase 3, randomized trial investigating NIVO + NACT + adjuvant ET in this clinical setting





中文字典-英文字典  2005-2009